GSK to buy stake in Novartis consumer-health joint venture for $13 billion
Glaxo’s boss has said that buying the Novartis holding, whose products include Sensodyne toothpaste, Theraflu cold medicine and Panadol pain relievers, would strengthen its consumer business.business Updated: Mar 27, 2018 15:07 IST
GlaxoSmithKline Plc, the UK’s biggest drugmaker, agreed to buy out Novartis AG’s stake in their consumer-health joint venture for $13 billion, rather than bidding for a Pfizer Inc unit.
The transaction marks one of the first big moves by both Glaxo chief executive officer Emma Walmsley, who took over last year, and Novartis CEO Vas Narasimhan, who rose to the top spot last month. Walmsley has emphasized the benefit of having the pharmaceutical, vaccine and consumer businesses under one umbrella, partly due to the drug industry’s volatility.
Glaxo’s boss has said that buying the Novartis holding, whose products include Sensodyne toothpaste, Theraflu cold medicine and Panadol pain relievers, would strengthen its consumer business. That’s even though the sector has experienced pressure on prices as drugstores and other retailers vie to get shoppers. Glaxo’s investors balked last year when Walmsley mentioned interest in the Pfizer unit, fearing that it might endanger the British drugmaker’s dividend.
Novartis had the right, starting this month, to require Glaxo to purchase its stake in the venture. The new agreement removes uncertainty surrounding that option, Glaxo said Tuesday.
The consumer business expects operating margins to improve and approach “mid-20s” percentages by 2022, Glaxo said.
The sale of the 36.5% stake in the venture, which was formed in 2015, should close in the second quarter, Basel, Switzerland-based Novartis said Tuesday in a statement. The sale will also strengthen Novartis’s ability to drive shareholder returns and make bolt-on acquisitions, Narasimhan said in the statement.
“While our consumer health-care joint venture with GSK is progressing well, the time is right for Novartis to divest a non-core asset at an attractive price,” Narasimhan said.
Narasimhan is focusing on finding breakthrough drugs for cancer and other diseases. Novartis reiterated in January that a decision on whether to spin off the Alcon eye-care division probably won’t come before the first half of 2019.
Glaxo is starting a review of its Horlicks unit and other consumer-health nutrition products to help fund the transaction and increase focus on the over-the-counter and oral-health categories. The company expects to conclude that process around the end of 2018.
Glaxo pulled out of the contest for Pfizer’s consumer-health unit last week in a development that leaves the US drugmaker with dwindling options to dispose of the business, which is valued at as much as $20 billion.
One factor in Glaxo’s decision not to pay the price Pfizer wanted was a potential transaction to buy out the Novartis holding, analysts at Bloomberg Intelligence wrote last week. Glaxo had said it would be interested in acquiring the stake if Novartis exercised its option to sell.